Literature DB >> 29909239

Approaches to target IgE antibodies in allergic diseases.

Bianca Balbino1, Eva Conde2, Thomas Marichal3, Philipp Starkl4, Laurent L Reber5.   

Abstract

IgE is the antibody isotype found at the lowest concentration in the circulation. However IgE can undeniably play an important role in mediating allergic reactions; best exemplified by the clinical benefits of anti-IgE monoclonal antibody (omalizumab) therapy for some allergic diseases. This review will describe our current understanding of the interactions between IgE and its main receptors FcεRI and CD23 (FcεRII). We will review the known and potential functions of IgE in health and disease: in particular, its detrimental roles in allergic diseases and chronic spontaneous urticaria, and its protective functions in host defense against parasites and venoms. Finally, we will present an overview of the drugs that are in clinical development or have therapeutic potential for IgE-mediated allergic diseases.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; Anaphylaxis; Antibody; Asthma; Atopic dermatitis; CD23; DARPins; FcεRI; FcεRII; Immunoglobulin; Omalizumab

Mesh：

Substances：

Year:  2018        PMID： 29909239     DOI： 10.1016/j.pharmthera.2018.05.015

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  18 in total

1.  The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Authors:  Bianca Balbino; Pauline Herviou; Ophélie Godon; Julien Stackowicz; Odile Richard-Le Goff; Bruno Iannascoli; Delphine Sterlin; Sébastien Brûlé; Gael A Millot; Faith M Harris; Vera A Voronina; Kari C Nadeau; Lynn E Macdonald; Andrew J Murphy; Pierre Bruhns; Laurent L Reber
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Past, present, and future of anti-IgE biologics.

Authors:  Pascal Guntern; Alexander Eggel
Journal:  Allergy       Date:  2020-04-21       Impact factor: 13.146

3.  Receptor-destroying enzyme (RDE) from Vibrio cholerae modulates IgE activity and reduces the initiation of anaphylaxis.

Authors:  Tatsuya Yamazaki; Masanori Inui; Keiko Hiemori; Susumu Tomono; Makoto Itoh; Isao Ichimonji; Akina Nakashima; Hidekazu Takagi; Mrityunjoy Biswas; Kumi Izawa; Jiro Kitaura; Teruko Imai; Nobuo Sugiura; Hiroaki Tateno; Sachiko Akashi-Takamura
Journal:  J Biol Chem       Date:  2019-03-04       Impact factor: 5.157

Review 4.  Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Authors:  Ana M Giménez-Arnau; Andaç Salman
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

Review 5.  Tracing IgE-Producing Cells in Allergic Patients.

Authors:  Julia Eckl-Dorna; Sergio Villazala-Merino; Nicholas James Campion; Maria Byazrova; Alexander Filatov; Dmitry Kudlay; Antonina Karsonova; Ksenja Riabova; Musa Khaitov; Alexander Karaulov; Verena Niederberger-Leppin; Rudolf Valenta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

Review 6.  Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.

Authors:  Gregorio Gomez
Journal:  Front Immunol       Date:  2019-02-07       Impact factor: 7.561

7.  Scrodentoid A Inhibits Mast Cell-Mediated Allergic Response by Blocking the Lyn-FcεRIβ Interaction.

Authors:  Fei Qian; Liuqiang Zhang; Shaodong Lu; Gaohui Mao; Fujiang Guo; Ping Liu; Jinwen Xu; Yiming Li
Journal:  Front Immunol       Date:  2019-05-16       Impact factor: 7.561

8.  The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.

Authors:  Pascal Gasser; Svetlana S Tarchevskaya; Pascal Guntern; Daniel Brigger; Rahel Ruppli; Noemi Zbären; Silke Kleinboelting; Christoph Heusser; Theodore S Jardetzky; Alexander Eggel
Journal:  Nat Commun       Date:  2020-01-08       Impact factor: 14.919

9.  An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases.

Authors:  Peipei Liu; Zhongzong Pan; Chunyin Gu; Xiaodan Cao; Xiaowu Liu; Jianjian Zhang; Zheng Xiao; Xueping Wang; Haibing Guo; Dianwen Ju; Su-Jun Deng
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

10.  IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against Staphylococcusaureus.

Authors:  Philipp Starkl; Martin L Watzenboeck; Lauren M Popov; Sophie Zahalka; Anastasiya Hladik; Karin Lakovits; Mariem Radhouani; Arvand Haschemi; Thomas Marichal; Laurent L Reber; Nicolas Gaudenzio; Riccardo Sibilano; Lukas Stulik; Frédéric Fontaine; André C Mueller; Manuel R Amieva; Stephen J Galli; Sylvia Knapp
Journal:  Immunity       Date:  2020-09-09       Impact factor: 43.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.